Choix du traitement immunosuppresseur : 2 cas cliniques et

More documents

Recommendations

Info

Simulect ® in Triple Therapy with • 6-month, double-blind, placebo-controlled, triple therapy (with MMF) • Interim results @ 3 months • 123 patients, 16 centers • Graft losses: 7 (still blinded) No deaths • No difference in adverse events MMF 40% 30% 20% 10% 0% * ASN 1999 % Acute rejection * 13.5% 25.0% Simulect ® Placebo
QUEL TRAITEMENT IMMUNOSUPPRESSEUR? • 1 CYCLOSPORINE • 2 TACROLIMUS • 3 SIROLIMUS • 4 BELATACEPT
Page 1 and 2: QUELS TRAITEMENTS IMMUNOSUPPRESSEUR
Page 3 and 4: Bilan prégreffe • Immunologie -
Page 5 and 6: • Pulmonaire - Primoinfection tub
Page 7 and 8: HOMEOSTASIE ET AGE J GORONZY Curr.
Page 9 and 10: • Donneur Greffe rénale préempt
Page 11 and 12: + + Simulect : 20 mg day 0 and day
Page 13 and 14: 50 40 30 20 10 0 ACUTE REJECTIONS O
Page 15 and 16: Meta-analysis of RCT comparing IL2R
Page 17 and 18: Delayed Graft Functiion (DGF) Acute
Page 20 and 21: En analyse multivariée OR 95% IC P
Page 22 and 23: Simulect ou absence de traitement d
Page 26 and 27: CYCLOSPORINE OU TACROLIMUS?
Page 28 and 29: Biopsy Proven Acute Rejection (ITT,
Page 30 and 31: Graft survival (%) Graft and Patien
Page 32 and 33: Group A n=71 Sirolimus (SRL) Load:
Page 34 and 35: ml/min SRL CsA 60 50 40 30 51,8 ±1
Page 36 and 37: Cyclosporine ou Belatacept?
Page 39 and 40: LEA29Y* CsA (7±3 mg/kg daily)* LEA
Page 41: Median Iohexol clearance (ml/min/1.
Page 44 and 45: Cellcept ou Azathioprine?
Page 46 and 47: Graft survival (%) 100 95 90 85 80
Page 48 and 49: STEROIDES OU NON?
Page 50 and 51: Immunosuppression sans corticoïdes
Page 52 and 53: R Tac 0.1mg/kg MMF 1g Dac 1mg/kg St
Page 54: Adverse events Tac+MMF (N=260) % Ta
Page 62: Evolution • Reprise normale de la
Page 65: CINETIQUE DES SOUS-POPULATIONS T CD

Choix du traitement immunosuppresseur : 2 cas cliniques et

Create successful ePaper yourself

Delete template?

Save as template?